Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.